CYTOKERATIN 5/6/18


ArtNr	20-783-71087
Hersteller	GENWAY
Menge	1 ml
Kategorie	Oncology Antibodies Cell Biology Cytoskeleton Immunohistochemistry Primary Antibodies Intermediate filaments By Organ Bone Cancer
Typ	Antibody
Applikationen	IHC
Clon	LP34
Specific against	other
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	GWB-336450
Similar products	20-783-71087
Lieferbar
Genway ID:	GWB-336450
Specificity:	CYTOKERATIN 5/6/18NCBI
Gene ID:	3853
Specificity:	CYTOKERATIN 5/6/18
Clone:	LP34
Immunogen:	Detergent-insoluble fraction of psoriatic human epidermis
Fusion Partner:	Spleen cells from immunised mice were fused with cells of the mouse p3-NSI-Ag4. 1 myeloma cell line.
Specificity Note:	This product recognises human cytokeratins 5 6 and 18. The antibody has a broad reactivity with epithelial tissues ranging from simple glandular epithelial to stratified squamous epithelial. This reagent is valuable for the identification of epithelial tumours.
Immunohistology:	This product requires protein digestion pre-treatment of paraffin sections e. g. trypsin. In frozen sections it recognises cytokeratin 5 6 and 18 with equal intensity but staining of cytokeratin 18 in paraffin-embedded tissues may be variable. Histology: Skin
Preservative Stabilisers:		15mMSodium Azide Reconstitution: Reconstitute with 1 ml distilled waterSuggested
Dilution:	Suggested
Dilution:	Immunohistology - Frozen - 1/100Immunohistology - Paraffin - 1/100
Subunit:	Heterotetramer of two type I and two type II keratins. Keratin-5 associates with keratin-14. Interacts with TCHP.
Disease:	Defects in KRT5 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering milia formation dystrophic nails and mucous membrane involvement.
Disease:	Defects in KRT5 are the cause of epidermolysis bullosa simplex with migratory circinate erythema (EBSMCE) [MIM:609352]. EBSMCE is a form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands feet and legs but spare nails ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS with no evidence of tonofilament clumping.
Disease:	Defects in KRT5 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
Disease:	Defects in KRT5 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type althought it is less severe.
Disease:	Defects in KRT5 are the cause of epidermolysis bullosa simplex with mottled pigmentation (MP-EBS) [MIM:131960]. MP-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and \' mottled\' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules.
Disease:	Defects in KRT5 are the cause of Dowling-Degos disease (DDD) [MIM:179850]; also known as Dowling-Degos-Kitamura disease or reticulate acropigmentation of Kitamura. DDD is an autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.
Miscellaneous:	There are two types of cytoskeletal and microfibrillar keratin: I (acidic; 40-55 kDa) and II (neutral to basic; 56-70 kDa).
Similarity:	Belongs to the intermediate filament family. 1. Ghosh. A. K. et al. (1985) Detection of metastatic tumour cells in routine bone marrow smears by immuno-alkaline phosphatase labelling with monoclonal antibodies.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 1 ml

lieferbar

Lieferung vsl. bis 11.09.2025

Express-Lieferung: 7 Tage sparen

Vergleichen

Auf den Wunschzettel

Angebot anfordern